Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:682117rdf:typepubmed:Citationlld:pubmed
pubmed-article:682117lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C0004927lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C0034838lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C1514758lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C1555903lld:lifeskim
pubmed-article:682117lifeskim:mentionsumls-concept:C0037791lld:lifeskim
pubmed-article:682117pubmed:issue2lld:pubmed
pubmed-article:682117pubmed:dateCreated1978-10-27lld:pubmed
pubmed-article:682117pubmed:abstractTextPharmacological stimulation of central serotonin (5-HT) receptors causes a behavioral syndrome characterized by simultaneous side-to-side head weaving or head tremor, forepaw padding and splayed hindlimbs. This syndrome has been proposed and used as a model for 5-HT receptor activity. Questions have been raised about the possible involvement of catecholamines. This study was designed to differentiate behavioral signs contributed by 5-HT from those that might be due to catecholamines. Depletion of catecholamines by alpha-methyl-p-tyrosine, or depletion of 5-HT by either p-chlorophenylalanine or 5,7-dihydroxytryptamine, did not prevent the syndrome caused by 5-methoxy-N,N-dimethyltryptamine, a 5-HT receptor agonist. Pretreatment with methysergide, but not phenoxybenzamine or pimozide, prevented the syndrome caused by 5-methoxy-N,N-dimethyltryptamine. Conversely, 5-HT depletion prevented the syndrome caused by monoamine oxidase inhibitor and levodopa; behavioral response was restored in p-chlorophenylalanine-pretreated rats by 5-hydroxytryptophan. Methysergide prevented the syndrome caused by monoamine oxidase inhibitor and levodopa, but phenoxybenzamine or pimozide did not. Intraventricular 5-HT or dopamine also caused the behavioral syndrome after monoamine oxidase inhibition. p-Chlorophenylalanine pretreatment prevented the syndrome caused by dopamine, but did not prevent the syndrome caused by 5-HT. Our results suggest that systemic levodopa or intraventricular dopamine produces the behavioral signs through 5-HT mechanisms; endogenous catecholamine mechanisms are not involved directly in either the cause or expression of the behavioral syndrome.lld:pubmed
pubmed-article:682117pubmed:languageenglld:pubmed
pubmed-article:682117pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:citationSubsetIMlld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:682117pubmed:statusMEDLINElld:pubmed
pubmed-article:682117pubmed:monthAuglld:pubmed
pubmed-article:682117pubmed:issn0022-3565lld:pubmed
pubmed-article:682117pubmed:authorpubmed-author:ConnorJ DJDlld:pubmed
pubmed-article:682117pubmed:authorpubmed-author:SloviterR SRSlld:pubmed
pubmed-article:682117pubmed:authorpubmed-author:DrustE GEGlld:pubmed
pubmed-article:682117pubmed:issnTypePrintlld:pubmed
pubmed-article:682117pubmed:volume206lld:pubmed
pubmed-article:682117pubmed:ownerNLMlld:pubmed
pubmed-article:682117pubmed:authorsCompleteYlld:pubmed
pubmed-article:682117pubmed:pagination339-47lld:pubmed
pubmed-article:682117pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-A...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-R...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-B...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-S...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-M...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-B...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-T...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-M...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-T...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-D...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-M...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-M...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-L...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-A...lld:pubmed
pubmed-article:682117pubmed:meshHeadingpubmed-meshheading:682117-R...lld:pubmed
pubmed-article:682117pubmed:year1978lld:pubmed
pubmed-article:682117pubmed:articleTitleSpecificity of a rat behavioral model for serotonin receptor activation.lld:pubmed
pubmed-article:682117pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:682117lld:pubmed